Newswise — Rockville, Md. – The Association for Research in Vision and Ophthalmology (ARVO) today announced the launch of a new fellowship for early-career researchers. The Mallinckrodt Uveitis Research Fellowship, generously funded by Mallinckrodt Pharmaceuticals, will support early career investigators with a one-year grant of $45,000 in their endeavor to investigate the impetus of uveitis or other inflammatory conditions in innovative ways.

“We are thrilled with Mallinckrodt’s initiative in funding this fellowship,” said ARVO Foundation Board of Governors Chair Paul Sternberg, Jr., MD, FARVO. “This program will allow for the theories and drive of promising young researchers to come to fruition in the form of extraordinary results in the treatment of uveitis. We look forward to seeing what the future recipients accomplish.”

This fellowship will allow ARVO members working in a nonprofit or academic research center the freedom to explore causes and components of uveitis and similar disorders in novel ways. The hope is that the generation of promising preliminary results will evolve into powerful findings, making their way into impactful publications and stimulating further insights and advances in the ocular inflammation space.

“Inflammatory eye diseases are a broad category with several different known and unknown causes,” said Tunde Otulana, MD, Chief Medical Officer of Mallinckrodt. “This fellowship aims to uncover the mechanisms behind conditions like uveitis, providing the vision community with vital information for additional research. We are honored to support the ARVO Foundation in fostering the next generation of answer seekers, treatment developers and cure finders.”

Applications for the fellowship will be open from July 1 to September 1, 2019.

For more information about the Mallinckrodt Uveitis Research Fellowship, visit ARVO’s website.


About ARVO: The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include nearly 12,000 eye and vision researchers from over 75 countries. ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders. Learn more at

About the ARVO Foundation: Established in 2001, the ARVO Foundation for Eye Research raises funds through partnerships, grants and sponsorships to support ARVO’s world-class education and career development resources for eye and vision researchers of all stages of career and education. Learn more at

About Mallinckrodt: Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reporting segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics. Its Specialty Generics and Amitiza reporting segment includes specialty generic drugs, active pharmaceutical ingredients and AMITIZA® (lubiprostone). To learn more about Mallinckrodt, visit

Register for reporter access to contact details